Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (canceled)

Claim 2 (canceled)

Claim 3 (previously presented) The method of claim 13, wherein the formulation comprises the ganglioside GM2, GM3, or GD1b.

Claim 4 (canceled)

Claim 5 (canceled)

Claim 6 (previously presented) The method of claim 13, wherein the formulation comprises 70-90% GD3 and 0-15% GM3 by weight based on total gangliosides.

Claim 7 (previously presented) The method of claim 13, wherein the formulation comprises about 80% GD3 and about 5% GM3 by weight based on total gangliosides.

Claim 8 (canceled)
Claim 9 (canceled)
Claim 10 (canceled)

Claim 11 (previously presented) The method of claim 13, wherein the formulation is in the form of a supplemented liquid or food.

Claim 12 (canceled)

Claim 13 (currently amended) A method for mediating inflammation in an adult subject in need thereof, having an inflammatory bowel disorder, having a disorder arising from an allergic response, having a disease involving an epithelial surface response, or having inflammation of the intestine, retina, or neuronal tissue,

the method comprising the step of providing a sufficient amount of a formulation for mediating inflammation, the formulation comprising one or more gangliosides, said gangliosides comprising GD3, to said subject for oral consumption at a dosage of up to 1 g of ganglioside per day;

wherein the percentage of GD3 as a function of total gangliosides is at least 50% by weight;

wherein mediating inflammation comprises changing lipid components in microdomains for treating inflammatory bowel disorders, disorders arising from allergic responses, diseases involving epithelial surface responses, or inflammation of the intestine, retina, or neuronal tissue; and

wherein changing lipid components comprises a reduction in platelet activating factor (PAF), a reduction in the ratio of cholesterol:sphingolipid, or a reduction in total diglyceride in the microdomains.

Claim 14 (canceled)
Claim 15 (canceled)
Claim 16 (canceled)

Claim 17 (previously presented) The method of claim 25, wherein the formulation comprises the ganglioside GM2, GM3, or GD1b.

Claim 18 (canceled)
Claim 19 (canceled)
Claim 20 (canceled)

Claim 21 (previously presented) The method of claim 25, wherein the formulation comprises 70-90% GD3 and 0-15% GM3 by weight based on total gangliosides.

Claim 22 (previously presented) The method of claim 25, wherein the formulation comprises about 80% GD3 and about 5% GM3 by weight based on total gangliosides.

Claim 23 (previously presented) The method of claim 25, wherein the formulation is in the form of a supplemented liquid or food.

Claim 24 (canceled)

Claim 25 (currently amended) A method for reducing plasma cholesterol level in an adult subject in need thereof with elevated plasma cholesterol, comprising the step of providing a sufficient amount of a formulation to reduce plasma cholesterol, the formulation comprising one or more gangliosides, said gangliosides comprising GD3, to said subject for oral consumption at a dosage of up to 1 g of ganglioside per day,

wherein the percentage of GD3 as a function of total gangliosides is at least 50% by weight, and

wherein plasma cholesterol is reduced by changing lipid components in microdomains by a reduction in platelet activating factor (PAF), a reduction in the ratio of cholesterol:sphingolipid, or a reduction in total diglyceride in the microdomains.

Claim 26 (canceled)

Claim 27 (canceled)

Claim 28 (currently amended) A method for mediating inflammation in an infant subject in need thereof having an inflammatory bowel disorder, having a disorder arising from an allergic response, having a disease involving epithelial surface responses, or having inflammation of the intestine, retina, or neuronal tissue,

the method comprising the step of providing a sufficient amount of a formulation for mediating inflammation, the formulation comprising one or more gangliosides, said gangliosides comprising GD3, to said subject for oral consumption at a dosage of up to 50 mg of ganglioside per day;

wherein the percentage of GD3 as a function of total gangliosides is at least 50% by weight;

wherein mediating inflammation comprises changing lipid components in microdomains for treating inflammatory bowel disorders, disorders arising from allergic responses, diseases involving epithelial surface responses, or inflammation of the intestine, retina, or neuronal tissue; and

wherein changing lipid components comprises a reduction in platelet activating factor (PAF), a reduction in the ratio of cholesterol:sphingolipid, or a reduction in total diglyceride in the microdomains.

Claim 29 (previously presented) The method of claim 28, wherein the formulation comprises the ganglioside GM2, GM3, or GD1b.

Claim 30 (previously presented) The method of claim 28, wherein the formulation comprises 70-90% GD3 and 0-15% GM3 by weight based on total gangliosides.

Claim 31 (previously presented) The method of claim 28, wherein the formulation is in the form of a supplemented liquid or food.

Claim 32 (previously presented) The method of claim 31, wherein the supplemented liquid or food comprises infant formula or infant foods.